Achillion Pharmaceuticals, Inc. (ACHN): What’s the Story?

Achillion Pharmaceuticals, Inc. (ACHN) is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $4.21, down from yesterday’s close by -0.47%. Given the stock’s recent action, it seemed like a good time to take a closer look at the company’s recent data.

Fundamental Analysis

Achillion Pharmaceuticals, Inc. (ACHN) currently trades with a market capitalization of $580.47 Million. That value represents a market adjusting for revenues that have been falling by -100.00 % on a quarterly year/year basis as of the company’s last quarterly report.

You can get a sense of how sustainable that is by a levered free cash flow of -$57.68 Million over the past twelve months. Generally speaking, earnings are expected to grow in coming quarters. Analysts are forecasting earnings of -$0.14 on a per share basis this quarter. Perhaps, that suggests something about why 0.21% of the outstanding share supply is held by institutional investors.

Technical Analysis

We’ve taken a serious look at this stock from a fundamental perspective, but the tale of the tape may offer more hints about what lies under the surface. Looking at the stock’s movement on the chart, Achillion Pharmaceuticals, Inc. recorded a 52-week high of $5.66. It is now trading 1.45% off that level. The stock is trading $3.09 its 50-day moving average by -1.12%. The stock carved out a 52-week low down at $2.58.

In recent action, Achillion Pharmaceuticals, Inc. (ACHN) has made a move of +45.17% over the past month, which has come on Strong relative transaction volume. Over the trailing year, the stock is underperforming the S&P 500 by 17.8, and it’s gotten there by action that has been less volatile on a day-to-day basis than most other stocks on the exchange. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 6.23% with $137.70 Million sitting short, betting on future declines. That suggests something of the likelihood of a short squeeze in shares of ACHN.

Previous articleThe Case for and Against Eleven Biotherapeutics, Inc. (EBIO)
Next articleAlly Financial Inc. (ALLY): What’s the Story?